Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis

Boldrini, Vinícius O.; Mader, Simone; Kümpfel, Tania; Meinl, Edgar

doi:10.1016/j.msard.2023.104733

Cited by 3 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A recently approved ublituximab is a notable exception in this DMT class and should not be administered to WwMS considering imminent pregnancy [73]. A negative pregnancy test is recommended prior to ublixuximab infusion, according to the FDA label.…”

Section: Pregnancymentioning

confidence: 99%

Pregnancy and reproductive health in women with multiple sclerosis: an update

Houtchens

2024

Current Opinion in Neurology

View full text Add to dashboard Cite

Purpose of the review Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, neuro-degenerative disease of the central nervous system, prevalent in women of reproductive age. Today, many women want to start a family after MS diagnosis. There are over 20 treatments for MS, and safely navigating family planning is important. We review updated information on family planning, preconception, and peri-partum considerations, and reproductive concerns in special populations with MS. Recent findings There are no MS-related restrictions on any available and appropriate contraceptive method in women with MS. The question of MS and pregnancy outcomes following assisted reproduction, remains somewhat unsettled. In many studies, no elevated relapse risk is confirmed regardless of the type of fertility treatment. MRI status may offer better assessment of postpartum disease stability than relapse rate alone. Ongoing effective MS treatments during fertility assistance and before pregnancy, can further reduce the relapse risk. B-cell depleting therapies are emerging as safe and effective treatments for peripartum MS patients. Summary Patients with MS should receive accurate support and counseling related to their reproductive options. The general outlook on pregnancy and MS remains positive. The ever-increasing therapeutic complexity of MS calls for ongoing education and updated guidance for neuroimmunology and obstetrics healthcare providers.

show abstract

Section: Pregnancymentioning

confidence: 99%

Pregnancy and reproductive health in women with multiple sclerosis: an update

Houtchens

2024

Current Opinion in Neurology

View full text Add to dashboard Cite

show abstract

Anti-CD20 monoclonal antibodies in multiple sclerosis: Rethinking the current treatment strategy

Freeman,

Zéphir

2024

Revue Neurologique

View full text Add to dashboard Cite

B‑lymphocyte‑targeted MS therapy: from theory to a decade of ocrelizumab in practice

Šťastná,

Seňavová,

Horáková

2024

Neurol. pro Praxi

View full text Add to dashboard Cite

Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis

Cited by 3 publications

References 18 publications

Pregnancy and reproductive health in women with multiple sclerosis: an update

Pregnancy and reproductive health in women with multiple sclerosis: an update

Anti-CD20 monoclonal antibodies in multiple sclerosis: Rethinking the current treatment strategy

B‑lymphocyte‑targeted MS therapy: from theory to a decade of ocrelizumab in practice

Contact Info

Product

Resources

About

Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis

Cited by 3 publications

References 18 publications

Pregnancy and reproductive health in women with multiple sclerosis: an update

Pregnancy and reproductive health in women with multiple sclerosis: an update

Anti-CD20 monoclonal antibodies in multiple sclerosis: Rethinking the current treatment strategy

B­‑lymphocyte­‑targeted MS therapy: from theory to a decade of ocrelizumab in practice

Contact Info

Product

Resources

About

B‑lymphocyte‑targeted MS therapy: from theory to a decade of ocrelizumab in practice